By Wall Street Breakfast : Economy Euro zone inflation continued to fall in August , with consumer prices rising just 0.3% Y/Y, well below the ECB's target of just below 2%. The new figures released by Eurostat boost expectations that the central bank will announce further stimulus measures, and ...
Aug 28 (Reuters) - Johnson & Johnson plans to seek a buyer for its medical device maker business, Cordis Corp, The Wall Street Journal reported citing people familiar with the matter.
Johnson & Johnson ( NYSE : JNJ ) is beginning the process of seeking ..... would mark the latest divestiture for JNJ , which is looking to shed slower-growth ..... businesses and reduce annual costs by $1B; JNJ said in 2011 it would leave the cardiac
Johnson & Johnson 's ( JNJ -0.3% ) DePuy Synthes unit recalls certain lots of its Craniomaxillofacial Distraction System also called External Mandibular
these 12 stocks-- Tyco TYC, Wal-Mart WMT, Johnson & Johnson JNJ , American Express AXP, and Time Warner TWX ..... Star Rating Tyco TYC 9 AIG AIG 9 Wal-Mart WMT 9 Johnson & Johnson JNJ 9 American Express AXP 8 Berkshire Hathaway BRK
Aug 28 (Reuters) - Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.
the two largest US pure pharma companies, Pfizer and Merck, as well as the Swiss heavyweights, Roche and Novartis. Only JNJ , which is a diversified conglomerate with large consumer health and medical device divisions, seems out of the near term
Aug 28 (Reuters) - Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw following more than a dozen cases of injury.
the introduction of newer, better therapies from Gilead and JNJ , only about 50,000 patients were treated. Therefore, with the approvals of Gilead's Sovaldi and JNJ 's Olysio, there was pent-up demand for these drugs
By Rajiv Puri : In early June, I put out an article , Advaxis Mirrors Imclone Systems Prior to Acquisition , which presented the Advaxis (NASDAQ: ADXS ) as an early stage prospective buyout by Big Pharma. The thesis was based on three mutual traits that Advaxis shared with Imclone that ultimately